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Vitamin D in Rheumatic Diseases:
Interpretation and Significance
Binit Vaidya and Shweta Nakarmi
Abstract
The pleiotropic effects of vitamin D on the various metabolic, anticancer, and
immunomodulatory functions of the body based on the presence of vitamin D
receptors (VDR) on various cell types has been recognized worldwide now. Of few
understood mechanisms of immunomodulatory actions of vitamin D are the
suppressive action on the maturation of antigen-presenting cells and decrease in the
levels of pro-inflammatory cytokines. Vitamin D deficiency has been implicated in
the immune diseases like rheumatic diseases, asthma, psoriasis, and multiple
sclerosis. Vitamin D deficiency has been associated with increased frequency and
severity of disease flares in rheumatic diseases like lupus and rheumatoid arthritis.
Other studies have shown higher prevalence of persistence and evolution in to more
definite rheumatic disorder in undifferentiated arthritis and undifferentiated
connective tissue disorder patients with vitamin D deficiency. Multiple factors like
avoidance of sunlight, the use of corticosteroids and hydroxychloroquine, skin
pigmentation, etc. should be considered when evaluating vitamin D levels in these
patients, needless to say the consideration of higher-dose supplement for these
patients. It is thus prudent that all patients with established or undifferentiated
rheumatic diseases are evaluated for vitamin D status and an adequate supplemen-
tation is recommended to prevent the associated consequences.
Keywords: vitamin D, vitamin D deficiency, immunomodulation,
rheumatic diseases, inflammation
1. Introduction
Vitamin D has two bioequivalent forms, D2 (ergocalciferol) and D3 (cholecal-
ciferol). It is synthesized mainly from 7-dehydrocholesterol in keratinocytes of the
skin stimulated by UVB of sunlight and metabolized in the liver to 25(OH)D and
subsequently converted to its active form 1,25(OH)2D in the kidney [1, 2]. It
maintains calcium and phosphorus homeostasis, optimizes bone health and muscle
function and immunomodulation, has antiproliferative effect on keratinocytes,
and suppresses cytokine production [3, 4]. Serum 25(OH)D3 level of at least
50 nmol/l is considered to be optimal for bone health and extra skeletal effects [5].
The term hypovitaminosis D includes vitamin D insufficiency and deficiency.
Vitamin D insufficiency is defined as a serum 25(OH)D concentration of 21–
29 ng/ml (50–75 nmol/L), whereas deficiency means serum 25(OH)D level of
<20 ng/ml (<50 nmol/L) [6].
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Vitamin D is also known as the sunshine vitamin. The importance of sunlight for
human health came into light with the industrial revolution in Northern Europe [7].
Sniadecki first published an article in 1822 about high prevalence of rickets in
children who lived in the inner city in comparison to those who lived in the rural
areas [8]. Many observations regarding the sun exposure and rickets have been
published in the course of time. Studies have also revealed the high prevalence of
vitamin D deficiency in general population, mostly owing to lack of sun exposure.
2. Vitamin D structure, synthesis, and metabolism
Vitamin D is a fat-soluble seco-steroid made from four cholesterol rings IOM
(Institute of Medicine) [9]. It has two bioequivalent forms, D2 (ergocalciferol) and
D3 (cholecalciferol). Vitamin D2 is derived from the plant sterol ergosterol [1, 9].
Vitamin D from the diet or dermal synthesis is biologically inactive [10]. Vitamin
D3 is synthesized mainly from 7-dehydrocholesterol in keratinocytes of the skin
stimulated by UVB of sunlight [3]. Under the influence of sunlight (ultraviolet
radiation, action spectrum 280–320 nM, or UVB), 7-dehydrocholesterol in the
epidermis is converted to vitamin D (Figure 1). Keratinocytes express the vitamin
D receptor (VDR) due to which they are capable of responding to the 1,25(OH)2D
produced [11]. Both UVB intensity and skin pigmentation level contribute to the
rate of D3 formation [12]. D3 is converted to 25(OH)D (calcidiol) in the liver by a
number of enzymes. 25-Hydroxyvitamins D2 and D3 produced by the liver enter
the circulation and the kidney bound to vitamin D-binding protein. The kidney
metabolizes 25(OH)D to the active metabolite 1,25(OH)2D3.
3. Sources of vitamin D
More than 90% of vitamin D requirement comes from sunlight. According to
Holick, exposure of ≥20% of the body’s surface to either direct sunlight or tanning
Figure 1.
Overview of vitamin D, UpToDate 2019.
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bed radiation is effective in increasing blood concentrations of vitamin D3 and
25-hydroxyvitamin D3 [25(OH)D3]. One minimal erythemal dose (MED) is equi-
valent to 10–50 times the recommended intakes [3]. Oily fishlike salmon, mackerel,
sardines, and cod liver oil are also considered good sources of vitamin D [13].
4. Causes of vitamin D deficiency
There are numerous causes of vitamin D deficiency. Decreased synthesis from
the skin is one of the main causes. Less exposure to sunlight, lifestyle, skin pigmen-
tation, abundant use of sunscreen lotion, and geographical variation owe to less
dermal synthesis. Decreased bioavailability due to malabsorption, decreased syn-
thesis of active form of vitamin D due to liver or renal failure, or increased catabo-
lism with the use of various medications like glucocorticoids and anticonvulsants
also cause deficiency. VDD is also seen in diseases like rickets, osteomalacia, hyper-
parathyroidism, and granulomatous disorders [14].
5. Daily recommended dose of vitamin D
The daily recommended allowance of vitamin D is 400–600 IU in children and
adults and 800 IU in adults >70 years [9].
6. Clinical applications
1.Bone and vitamin D: Vitamin D maintains calcium and phosphorus
homeostasis and optimizes bone health and muscle function [4]. Adequate
vitamin D is necessary to prevent rickets and osteomalacia [3]. Though still
controversial, it is reported that calcium and vitamin D supplementation
prevents fall risk and also decreases the osteoporotic fracture in older adults
[15]. Vitamin D supplementation of 700–800 IU per day reduces falls and
fractures in older adults [16].
2.PTH and vitamin D: There is an inverse relationship between circulating 25
(OH)D levels and parathyroid hormone (PTH) [1].
3.Muscle function and vitamin D: There are several studies that suggest a
relationship between vitamin D and muscle function. Though improvement of
muscle strength with supplementation of vitamin D has been observed in few
trials [17, 18], the causal relation has not been established yet.
4.Skin and vitamin D: 1,25(OH)2D analogs calcipotriol and maxacalcitol can be
used for the treatment of the hyperproliferative skin diseases like psoriasis
[3, 19] and non-melanoma skin cancer [20].
5.Cancer and vitamin D: Vitamin D deficiency has been associated with cancers,
especially colorectal [21, 22]. Calcium and 1,25(OH)2D3 participate in the
regulation of keratinocyte proliferation and differentiation and may prevent
the development of skin cancer [20]. Observational studies have shown the
relationship between vitamin D deficiency and carcinoma of the breast, colon,
and thyroid [3], but the results are not consistent.
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6.Immune system and vitamin D: Vitamin D is a potent immunomodulator. 1,25
(OH)2D decreases the maturation of dendritic cells (DCs) decreasing their
ability to present antigen and to activate T cells [23]. Furthermore, it
suppresses production of IL-12 (important for Th1 development), IL-23, and
IL-6 (important for Th17 development) [24]. But, there is no any approved
vitamin D drug for immune modulation [1]. Studies have suggested an
association of vitamin D with autoimmune diseases like multiple sclerosis [25]
and asthma [26].
7.Cardiovascular disease and vitamin D: There is an inverse relationship between
vitamin D deficiency and risk of heart disease, myocardial infarction, and early
death. Low vitamin D causes increased parathyroid hormone release,
inflammation, proliferation of vascular smooth muscle cells, insulin resistance,
thrombogenicity, dyslipidemia, and progressive extracellular matrix
remodeling. All of these are associated with increased risk of ischemic heart
disease, myocardial infarction, and early death [27, 28].
8.Diabetes mellitus and vitamin D: Vitamin D deficiency is associated with
insulin resistance. 1,25(OH)2D promotes increased lipogenesis and decreased
lipolysis. The pancreatic B cell expresses the VDR, and 1,25(OH)2D promotes
insulin secretion [29].
9.Neurological disorder and vitamin D: Vitamin D plays an important role in
brain development as it has effects on neuronal proliferation, differentiation,
migration, and apoptosis [30].
7. Vitamin D and immunomodulation
Vitamin D is involved in modulation of immune responses and has an
important role in some autoimmune diseases like multiple sclerosis, diabetes
mellitus, psoriasis, systemic lupus erythematosus (SLE), RA, etc. [31]. The biologi-
cal effects or immunomodulation is mediated by the vitamin D receptor (VDR)
which belongs to the nuclear hormone receptor family and is expressed in most cell
types including macrophages, dendritic cells, B and T lymphocytes, and neutrophils
[31, 32].
Along with the modulatory effects on T and B cell functions, VDR agonists
inhibit the differentiation and maturation of DCs, thus influencing the function of
DCs and promoting tolerogenic properties that favor the induction of regulatory T
cells. VDR also downregulate expression of the costimulatory molecules CD40,
CD80, and CD86, decrease production of IL-12, and increase production of IL-10.
The inhibition of DC differentiation and maturation and production of pro-
inflammatory mediators play an important role in the immunoregulatory activity of
1,25(OH)2D3 [33, 34].
1,25(OH)2D3 also plays an important role in the maintenance of B cell homeo-
stasis. It has potent effects on functions of B cell, including induction of apoptosis
and inhibition of proliferation, generation of memory B cells, plasma cell differen-
tiation, and immunoglobulin production [35].
According to Grant, there is evidence in support of vitamin D reducing the risk
of many autoimmune diseases including such as multiple sclerosis and type 1 dia-
betes mellitus. However, evidence for rheumatoid arthritis, osteoarthritis, type 2
diabetes mellitus, hypertension, and stroke is weak [36].
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8. SLE
Vitamin D deficiency is quite prevalent in SLE patients which may be attribut-
able to various reasons. Avoidance of sunshine, photoprotection, renal insuffi-
ciency, and the use of medications which alter the metabolism of vitamin D or
downregulate the functions of the vitamin D receptor like glucocorticoids, anticon-
vulsants, antimalarials, and the calcineurin inhibitors are some of the causes of VDD
as shown in Figure 2 [37]. In a study by Toloza, vitamin D insufficiency was found
in 66.7% and deficiency in 17.9% of SLE patients [38]. The frequency varied in
different studies: Saudi Arabia (89.7%) [39], Norway (82%) [40], Poland (71%)
[41], Hong Kong (27%) [42], and the United States (20%) [43]. Low serum vitamin
D levels were related to cumulative glucocorticoid dose [38]. Corticosteroids accel-
erate the catabolism of 25(OH)D and 1,25(OH)2D and have a significant role in
secondary osteoporosis [44]. Patients taking corticosteroids often require higher
daily doses of vitamin D to maintain adequate levels [45]. Similarly, a commonly
used antimalarial, hydroxychloroquine (HCQ), inhibits conversion of 25(OH)D to
1,25(OH)2D leading to low levels of vitamin D [46].
A review by Sakthiswary demonstrated a substantial evidence in support of
the association between vitamin D levels and SLE disease activity. However, vita-
min D level is not associated with organ damage [47]. A study by Suzan showed a
significant negative correlation that existed between 25(OH)D and anti-dsDNA and
a positive correlation between 25(OH)D levels and C4 [48]. Another similar study
showed a significant negative correlation between the serum concentration of
vitamin D and the standardized values of disease activity scores as measured by the
SLEDAI-2K and ECLAM scales [49]. An Australian study showed that low vitamin D
Figure 2.
The two-sided relation between vitamin D and SLE showing that low levels of vitamin D resulted from SLE and
SLE complications that come from vitamin D deficiency [37].
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was associated with a higher disease activity and an increase in serum vitamin D was
associated with reduced disease activity over time [50]. Improving vitamin D status
may improve other commonmanifestations as well, such as fatigue [51] and cognitive
dysfunction [52].
9. RA
The role of hypovitaminosis D in the pathogenesis of rheumatoid arthritis has
been the topic of interest in the recent past. Lower vitamin D levels possess
increased risk for RA [53]. 1,25(OH)2D3 contributes to the regulation of matrix
metalloproteinase and prostaglandin E2 production by synovial fibroblasts and
articular chondrocytes in RA [54].
High rates of vitamin D deficiency have been observed in patients with rheu-
matic diseases. A study demonstrated that in patients with RA, VDD was seen in
64% and insufficiency in 28%. Similarly, in spondyloarthritis (SpA) patients 48%
had VDD and 35% had insufficiency [55]. The prevalence of VDD is quite in RA
patients. The COMEDRA study showed that 55.8% of RA patients had vitamin D
insufficiency and 3.6% had deficiency [56]. Eighty-four percent of RA patients were
VDD in a recently published study by Meena. It also showed a significant inverse
correlation between serum vitamin D levels and RA disease activity [57]. A meta-
analysis by Lee and Bae supported this result suggesting that the vitamin D level is
associated with susceptibility to RA and RA activity [58]. Similarly, a negative
association between serum vitamin D and RA disease activity was demonstrated in
few studies [59–62]. Levels of 25(OH)D3 were also found to be negatively corre-
lated to CRP and ESR [62]. However, relationship between 25(OH)D and levels of
rheumatoid factor or anti-cyclic citrullinated peptide antibodies has not been
established yet [63].
The COMORA study showed that vitamin D was insufficient in 54.6% and
deficient in 8.5% of the RA patients. Low levels of vitamin D were associated with
disease activity of RA and corticosteroid dosage and comorbidities like lung disease
and osteoporosis therapy [64].
10. CTD
In comparison to healthy adults, VDD is more prevalent in people with autoim-
mune diseases including connective tissue diseases (CTDs) [65]. It may also have a
pivotal role in progression of undifferentiated CTDs to well-defined and more
severe disease [65]. There are few evidences which showed the antifibrotic property
of vitamin D [66]. Low vitamin D levels are also associated with more severe
disease, low diffusing capacity for carbon monoxide (DLCO), and advanced-stage
nailfold capillaroscopy changes in patients with scleroderma [67, 68]. However, a
recent meta-analysis revealed that though VDD is quite common in scleroderma
patients, it does not correlate to the disease activity [69].
Over the years, it has been proven that vitamin D is necessary for optimum
muscle and bone health. In CTDs, vitamin D levels correlate with intensity of
muscle weakness [68, 70]. It may also be considered as one of the risk factors in
developing myositis [71]. However, the role of vitamin D in myositis or other CTDs
has not been established yet. Studies have shown that in fibromyalgia, VDD is
correlated with pain and disease activity [72] and correction of deficiency improves
the symptoms [73].
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11. Undifferentiated arthritis
Significant association has been reported between vitamin D deficiency and
nonspecific musculoskeletal pain, arthralgias, or undifferentiated arthritis [74, 75].
A positive correlation of VDD with undifferentiated arthritis [76] and early inflam-
matory arthritis [77] has been observed. It has also shown VDD as one of the risk
factors of disease progression to RA [76, 78].
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